A5007103603- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Urological Disorders and Treatments
- Renal cell carcinoma treatment
- Renal and Vascular Pathologies
- Pediatric Urology and Nephrology Studies
- Prostate Cancer Diagnosis and Treatment
- Urologic and reproductive health conditions
- Renal and related cancers
- Ureteral procedures and complications
- Prostate Cancer Treatment and Research
- Esophageal Cancer Research and Treatment
- Urinary Tract Infections Management
- Testicular diseases and treatments
- Urinary Bladder and Prostate Research
- Kidney Stones and Urolithiasis Treatments
- Epigenetics and DNA Methylation
- Adrenal and Paraganglionic Tumors
- Cardiac, Anesthesia and Surgical Outcomes
- MRI in cancer diagnosis
- Cancer Genomics and Diagnostics
- Lymphoma Diagnosis and Treatment
- Cancer Research and Treatments
- Endometriosis Research and Treatment
- Colorectal Cancer Screening and Detection
Charles University
2009-2024
General University Hospital in Prague
2014-2021
Karcinom penisu je onemocněním, které má v České republice velmi nízkou incidenci.Z tohoto důvodu vhodné, aby pacienti s touto diagnózou byli soustředěni a léčeni na pracovištích, kde personál tímto onemocněním zkušenosti.Tato centralizace péče vede k lepším onkologickým výsledkům.V práci prezentována nová histopatologická klasifikace premaligních lézí, která usnadňuje zpřesňuje indikace operační léčbě poslední aktualizace TNM klasifikace.V článku předkládají autoři přehled možností...
Ta grade 3 (G3) non–muscle-invasive bladder cancer (NMIBC) is a relatively rare diagnosis with an ambiguous character owing to the presence of aggressive G3 component together lower malignant potential component. The European Association Urology (EAU) NMIBC guidelines recently changed risk stratification for from high intermediate, high, or very risk. However, prognostic studies on carcinomas are limited and inconclusive. To evaluate value categorizing compared G2 T1 carcinomas. Individual...
<b><i>Objectives:</i></b> To determine the combination of urinary protein markers for noninvasive detection primary and recurrent urothelial bladder carcinomas. <b><i>Methods:</i></b> Urinary concentrations 27 biomarkers (NSE, ATT, AFABP, Resistin, Midkine, Clusterin, Uromodulin, ZAG2, HSP27, HSP 60, NCAM1/CD56, Angiogenin, Calreticulin, Chromogranin A, CEACAM1, CXCL1, IL13Ra2, Progranulin, VEGFA, CarbAnhydIX, Annexin-V, TIM4, Galectin1,...
Objective: To evaluate the prognostic value of depth lamina propria invasion in patients with T1 bladder cancer. Subjects and Methods: 200 were treated between years 2002 2009. Tumours above muscularis mucosae level categorised as pT1a those up to or beyond pT1b. Results: Categorisation for pT1b was performed 176 (88%). In 10 a muscle-invasive tumour found re-transurethral resection samples. 131 (79%) 166 analysed had 35 (21%) tumour. During follow-up, 101 (61%) recurred 27 (16.3%)...
To evaluate the prognostic value of T1 subclassification and fascin-1 expression in human urothelial cell carcinoma bladder.In a prospective study with 105 consecutive patients, tumors were subclassified into 2 groups according to depth tumor invasion. The tunica muscularis mucosae was used as landmark. examined by using an anti-fascin-1 mouse monoclonal antibody evaluated semiquantitatively for both intensity distribution. patients followed up 27.3 +/- 13.7 months.The feasible 99 (94%). T1a...
<b><i>Objective:</i></b> To determine a predictive model for the primary diagnosis of prostate cancer (PC) based on multiple serum biomarker assay. <b><i>Material and Methods:</i></b> Between August 2011 February 2013, total 387 biopsies were performed. Serum or plasma concentrations 22 biomarkers (neopterin, IGF-1, IGFBP-2, IGFBP-3, sarcosine, endoglin, TGF-β1, periostin, sPLA2-IIa, chromogranin A, ZAG2, clusterin, PSP94, PSP94bp, leptin,...
Aim of the study is to define diagnostic accuracy selected urinary protein biomarkers in non-invasive detection primary and recurrent urothelial carcinoma bladder.The levels calprotectin, CD147, APOA4 deglycase DJ-1 were examined 255 individuals, including 60 controls with non-malignant urological disease, 61 patients a history bladder cancer negative cytology cystoscopy 134 cancer.Urinary concentrations determined by Enzyme-Linked Immunosorbent Assay (ELISA).During follow-up non-muscle...
We report on a 61-year-old woman with history of right-sided nephrectomy for clear cell renal carcinoma (RCC) occurring 21 years ago; she currently presented bilateral ovarian tumour. Histologically, the tumour both ovaries was carcinoma. Immunohistochemically, cells were positive vimentin, RCC marker, epithelial membrane antigen, cytokeratin AE1/3 and CD10. Cytokeratin 7, CA125, HMWCK, estrogen progesterone receptors all negative. Based morphologyand immunophenotype tumour, we established...
To evaluate the diagnostic accuracy and prognostic performance of urinary plasma levels placental growth factor (PLGF) provide their comparison with results vascular endothelial A (VEGF-A) in patients primary recurrent bladder cancer.The enzyme-linked immunosorbent assay (ELISA) was used to assess concentrations PLGF VEGF-A 240 individuals.PLGF urine were significantly higher cancer than healthy individuals (p=0.003, p=0.005, respectively). Area under curve (AUC) 0.68; AUC 0.65. Patients...